PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.

Front Immunol · 2022 · PMC9393421 · PMID 36003374

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A sub-group analysis of the KEYNOTE 590 study implied that the OS of PD-1+DDP was prolonged in the esophageal adenocarcinoma sub-group, but this did not reach statistical significance, while in the esophageal squamous cell carcinoma sub-group, the OS of PD-1+DDP was significantly better than that of chemotherapy alone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.